Drug-Induced Uveitis

Uveitis means inflammation inside the eye, especially of the uveal tract (the iris, ciliary body, and choroid), but the inflammation can involve other parts like the retina or vitreous. When any of these structures swell or become irritated, it causes symptoms like eye pain, redness, light sensitivity, and vision problems. Uveitis is important because, if untreated or unrecognized, it can damage the eye and cause permanent vision loss. The causes of uveitis are many—infectious germs, autoimmune diseases, systemic inflammatory conditions, and sometimes no cause is found at all. In a small but clinically important number of cases, medicines (including drugs given through the body, eye drops, injections into the eye, or even vaccines) trigger this inflammation; that specific situation is called drug-induced uveitis. Drug-induced uveitis is relatively rare (less than 0.5% of uveitis cases in referral clinics), but it can be missed unless the treating clinician specifically considers medications as a possible cause. Recognizing the drug as the trigger is critical because stopping or changing the offending medicine, often along with treating the inflammation, usually leads to resolution. EyeWiki Dove Medical Press NCBI

Uveitis means inflammation of the uvea, the middle layer of the eye that includes the iris, ciliary body, and choroid. When this inflammation is caused or triggered by a medication, it is called drug-induced uveitis. It can affect the front (anterior), middle (intermediate), back (posterior), or all parts of the eye (panuveitis). The inflammation can cause redness, pain, light sensitivity, blurred vision, floaters, and in severe or untreated cases, permanent vision loss. Early recognition and proper management are essential to prevent complications. PMC

Drug-induced uveitis happens because certain drugs alter immune responses, directly irritate ocular tissues, or cause autoimmune-like reactions. Some medications activate T cells, stimulate pro-inflammatory cytokines (like interleukin-6 or TNF-α), or disrupt immune tolerance, leading the body to attack parts of the eye. For example, nitrogen-containing bisphosphonates may activate antigen receptors on T lymphocytes, releasing inflammatory mediators that cause uveitis. PMCPMC

---

Pathogenesis

Drug-induced uveitis happens by different biological routes. Broadly, the mechanisms are divided into direct and indirect effects. A direct mechanism means the drug (or its formulation) reaches the inside of the eye directly—for example, when it is put on the eye surface, injected inside the eye, or otherwise accesses intraocular tissues. The irritation may come from the drug itself, a breakdown product, or even the carrier that carries the drug, and it causes a breach in the normal blood-ocular barrier leading to inflammation. An indirect mechanism means the drug triggers the immune system or other downstream effects outside the eye that secondarily cause inflammation inside the eye. Indirect pathways include immune complex deposition in uveal tissue (where drug-related antibodies form and lodge in the eye), immune reactions to antigens released when bacteria die after antibiotics (e.g., a “Jarisch-Herxheimer”-like response), alteration of melanin’s capacity to detoxify free radicals when drugs bind to melanin, or systemic immune modulation such as with immune checkpoint inhibitors that disinhibit T cells. Some drugs can paradoxically trigger inflammation when they would otherwise treat it (for example, certain biologic agents used for inflammatory diseases). PMCPMC

Clinically, uveitis is also described by where in the eye the inflammation is located. These anatomic types are: anterior uveitis (front of the eye: iris and ciliary body), intermediate uveitis (vitreous and pars plana region), posterior uveitis (retina and choroid), and panuveitis (inflammation in all segments). Drug-induced inflammation can present in any of these patterns depending on the offending agent and mechanism; some drugs more commonly cause front-of-eye (anterior) inflammation, while others can produce posterior or even diffuse (panuveitis) patterns. NCBI

---

Causes (Drugs and Agents That Can Trigger Uveitis)

Below are twenty distinct drug-related causes or categories known to induce uveitis, with a simple explanation of each and how they trigger inflammation:

1. Rifabutin – An antibiotic used especially in immunocompromised patients for Mycobacterium avium complex. It commonly causes anterior uveitis, sometimes with pus in the front chamber (hypopyon), and can rarely cause intermediate or posterior inflammation. The reaction seems related to immune changes and may be dose- and duration-dependent; concomitant drugs affecting its metabolism increase risk. EyeWikiDove Medical Press

2. Cidofovir – An antiviral used for CMV retinitis; systemic use (especially intravenous) can cause non-granulomatous anterior uveitis often with low eye pressure (hypotony). The mechanism is thought to involve toxic effects on the ciliary body after breakdown of the blood-ocular barrier. NCBIDove Medical Press

3. Bisphosphonates (e.g., zoledronate, pamidronate, alendronate) – Drugs for osteoporosis and bone disease can provoke ocular inflammation including uveitis, scleritis, or orbital inflammation. This is usually via immune complex–like cytokine release (acute phase reactant) and other immune-mediated pathways, particularly after initial doses. Dove Medical Press

4. Immune Checkpoint Inhibitors (e.g., anti–PD-1/PD-L1, anti–CTLA-4 therapies used in cancer) – These drugs unleash T cells to attack tumors but can also cause the immune system to attack normal tissues, including the eye, leading to anterior, posterior, or panuveitis. The inflammation can mimic autoimmune uveitis. ResearchGateMDPI

5. Tumor Necrosis Factor (TNF) Inhibitors, especially Etanercept – Although used to treat inflammatory disease (and sometimes uveitis), some TNF blockers paradoxically trigger new uveitis or worsen existing inflammation. Etanercept has the highest reported rate of inducing uveitis among TNF inhibitors, possibly related to its different immune modulation compared to monoclonal antibodies. Dove Medical Press

6. Fluoroquinolones (especially moxifloxacin) – These systemic antibiotics have been associated in some studies with uveitis onset, potentially through immune-mediated or idiosyncratic pathways. EdHub

7. Sulfonamides – Certain sulfa drugs (systemic) have been linked to anterior uveitis; the causes may be immune-mediated hypersensitivity reactions. EyeWiki

8. Interferon-alpha – Used in hepatitis and other conditions, interferon therapy can cause immune activation leading to ocular inflammation including uveitis, likely through autoimmune-type mechanisms. (Implicit in broader medication-induced uveitis reviews; similar immunomodulatory agents have known ocular side effects.) SpringerOpen

9. Topical Prostaglandin Analogues (e.g., latanoprost) – Eye drops for glaucoma can sometimes cause or exacerbate anterior uveitis, particularly in susceptible individuals, via local inflammatory pathways. EdHub

10. Brimonidine – A topical glaucoma medicine; in rare cases it can trigger inflammation in or around the eye, including a uveitis-like picture, through local immune or allergic reactions. EyeWiki

11. Intraocular Anti-VEGF Agents (e.g., brolucizumab, ranibizumab, aflibercept, faricimab, bevacizumab) – Injected into the eye for retinal vascular diseases, these can cause sterile intraocular inflammation mimicking uveitis, including anterior and posterior signs; some agents (like brolucizumab) have higher reported rates of retinal vasculitis or occlusive inflammation. Dove Medical Press

12. Intraocular Vancomycin – Used during eye surgery or injections, in some cases it has been implicated in toxic or immune-mediated inflammation resembling uveitis or sterile endophthalmitis. Dove Medical Press

13. Vaccines (e.g., BCG and other vaccines) – Certain immunizations have been reported to cause uveitis, likely via immune stimulation or molecular mimicry; the inflammation may appear days to weeks after vaccination. AAO

14. Biologic Agents Causing Sarcoid-like Reactions – Some drugs (including certain TNF blockers) can trigger sarcoid-like granulomatous inflammation that includes uveitis as part of the systemic mimicry, blurring the line between drug effect and induced systemic disease. Dove Medical Press

15. Systemic Antibiotics with Idiosyncratic Immune Effects (other than the ones above, such as certain macrolides when combined and leading to immune modulation) – Antibiotics can occasionally lead to ocular immune activation indirectly; for example, combinations altering immune status or causing bacterial component release can provoke uveitis-like inflammation. PMC

16. Immune-modulating Cancer Therapies beyond Checkpoint Inhibitors – Other newer targeted therapies (e.g., some kinase inhibitors) can alter immune signaling and, in rare cases, have been linked to uveitis by altering immune tolerance or triggering cytokine-mediated inflammation. Dove Medical Press

17. Drug-induced Immune Complex Deposition Agents (example: nitrogen-containing bisphosphonates beyond their acute cytokine effects) – These can cause delayed inflammation by forming complexes that lodge in the uveal tissue, causing a secondary immune response. PMC

18. Agents Altering Melanin Handling of Free Radicals – Some drugs bind to ocular melanin and change its protective antioxidant functions, leading to oxidative stress and subsequent uveitis; this is a proposed mechanism in certain pigment-associated differences in drug reaction. PMC

19. Paradoxical Drug Effects (e.g., drugs used for systemic inflammatory diseases) – Some medications intended to suppress inflammation can, in rare situations, cause new inflammation in the eye, as seen with certain biologics beyond TNF inhibitors, likely due to shifts in immune balance. Dove Medical Press

20. Topical or Intracameral Vehicles/Toxins – Sometimes the carrier or preservative of an eye drop or intraocular injection (not the active drug itself) can breach ocular barriers or trigger local toxic/immune inflammation that presents as uveitis. PMC

(For many of the above, establishing causality uses criteria such as the Naranjo adverse drug reaction scale: improvement when the drug is stopped, recurrence on rechallenge, exclusion of other causes, etc.) EyeWiki

---

Symptoms of Drug-Induced Uveitis

Drug-induced uveitis causes the same basic ocular symptoms as other types of uveitis. Below are 15 common symptoms, each explained simply:

1. Eye Redness – The white part of the eye turns pink or red because the blood vessels swell from inflammation. This is often one of the first obvious signs. NCBI

2. Eye Pain – Patients feel aching, sharp, or deep eye discomfort due to inflammation of sensitive internal structures like the iris or ciliary body. Movement, light exposure, or focusing may worsen it. NCBI

3. Photophobia (Light Sensitivity) – Bright lights hurt or feel uncomfortable because the inflamed iris cannot properly control the amount of light entering the eye, and the inflammation irritates photoreceptors. NCBI

4. Blurred Vision – Vision becomes fuzzy or unclear because the inflammation disturbs the clarity of the visual axis, causes swelling (e.g., macular edema), or interferes with normal eye optics. NCBI

5. Floaters – Tiny spots, strings, or cobweb-like shadows drift across vision due to inflammatory cells and debris in the vitreous gel. This is especially common when inflammation extends into the middle or back parts of the eye. NCBI

6. Decreased Vision – A measurable drop in how well a person can see, which can be due to any combination of inflammation, swelling, or damage to critical visual structures like the retina. NCBI

7. Tearing (Excessive Watery Eye) – Reflex tearing occurs because of irritation and inflammatory signaling from internal eye inflammation. NCBI

8. Eye Discomfort or Grittiness – A vague sensation of something being wrong in the eye, often from low-grade inflammation or associated surface irritation. NCBI

9. Changes in Pupil Shape or Reaction – Inflammation can cause the iris to stick to the lens (posterior synechiae), making the pupil irregular or sluggish in response to light. NCBI

10. Ciliary Flush – A ring of deep redness around the cornea, due to inflammation of the deeper vessels near the iris, distinguishing it from superficial redness of conjunctivitis. NCBI

11. Photopsia (Flashes of Light) – Patients may see brief flashes caused by retinal irritation or traction from inflammation in posterior parts of the eye. NCBI

12. Haloes around Lights – Light sources appear with colored rings or glare, often due to corneal or lens changes secondary to inflammation or increased protein (“flare”) in the aqueous humor. NCBI

13. Foreign Body Sensation – The patient feels as if something is in the eye, which can be due to irritation from cells or protein in the anterior chamber. NCBI

14. Systemic Symptoms (sometimes) – If the drug causes broader immune activation, some patients might have mild fever, fatigue, or malaise concurrent with eye inflammation, especially with systemic agents like bisphosphonates or checkpoint inhibitors. Dove Medical Press

15. Visual Field Loss or Peripheral Vision Changes – Especially with posterior or panuveitis, parts of the visual field may be reduced due to retinal or choroidal involvement. NCBI

---

Diagnostic Tests for Drug-Induced Uveitis

Physical Examination Tests 

1. Visual Acuity Testing – Measures clarity of vision using standardized charts to quantify how much the inflammation is affecting central vision. NCBI

2. Slit Lamp Biomicroscopy – A specialized microscope with a focused light beam to look at the front of the eye. This detects inflammatory cells and protein (“flare”) in the anterior chamber, keratic precipitates, and posterior synechiae. NCBI

3. Intraocular Pressure Measurement – Checks pressure inside the eye. Uveitis can lower or sometimes raise eye pressure; monitoring helps guide treatment and avoid complications like glaucoma. NCBI

4. Dilated Fundus Examination – Eye drops widen the pupil so the doctor can inspect the retina and optic nerve for inflammation, lesions, or vasculitis in posterior uveitis. NCBI

5. Pupil Examination and Assessment for Synechiae – Looking for irregular pupils or adhesions of the iris to the lens, which are signs of intraocular inflammation and prior episodes. NCBI

Manual / Clinical Functional Tests 

6. Swinging Flashlight Test (Afferent Pupillary Defect) – Checks the integrity of the visual pathway; severe posterior inflammation can blunt responses. Nature

7. Amsler Grid or Central Vision Screening – Simple grid used by patients or clinicians to detect distortion or central visual changes that might suggest macular involvement from posterior uveitis. (Standard clinical practice; inferred from how vision is monitored in uveitis.) NCBI

8. Color Vision Testing – Inflammatory or retinal damage can alter color perception, helping indicate posterior segment involvement. Nature

9. Visual Field Testing (Confrontation or Formal Perimetry) – Assesses peripheral vision loss that may occur with posterior inflammation or optic nerve involvement. NCBI

Laboratory / Pathological Tests 

10. Syphilis Serology (RPR/FTA-ABS) – Syphilis is a “great masquerader” and must be ruled out because it can present like uveitis; blood tests help confirm or exclude it. NCBI

11. HLA-B27 Typing – Genetic marker associated with specific autoimmune causes of anterior uveitis; useful when recurrent or bilateral inflammation is present. NCBI

12. Chest Imaging (X-ray or CT) + ACE/Lysozyme – Used to screen for sarcoidosis or tuberculosis, both of which can present with uveitis; ACE and lysozyme are blood markers and imaging helps detect granulomatous disease. NCBI

13. Quantiferon-TB Gold or PPD Skin Test – Evaluates latent or active tuberculosis, especially in posterior or panuveitis where TB is on the differential. NCBI

14. General Inflammatory Markers (ESR, CRP) – Though non-specific, elevated markers support a systemic inflammatory process and help guide further testing. NCBI

15. Autoimmune Panel (ANA, Rheumatoid Factor, etc.) – Helps if a systemic autoimmune disease is suspected to explain recurrent or atypical uveitis. NCBI

Electrodiagnostic Tests 

16. Electroretinography (ERG) – Measures electrical responses of the retina. In cases where posterior uveitis affects retinal function, ERG provides an objective measure of dysfunction or recovery over time. PMCResearchGate

17. Visual Evoked Potentials (VEP) – Tests the visual pathway from the retina through the optic nerve to the visual cortex; can reveal dysfunction when inflammation affects deeper pathways or optic nerve. NatureSpringerLink

18. Electro-oculography (EOG) / Multifocal ERG or Multifocal VEP – Specialized variants that can detect localized retinal or macular dysfunction, useful in chronic or subtle posterior inflammation. ResearchGate

Imaging Tests 

19. Optical Coherence Tomography (OCT) – A non-invasive imaging that gives a cross-sectional view of the retina and macula, detecting fluid buildup (macular edema), structural damage, or inflammatory signs. NCBI

20. Fluorescein and Indocyanine Green Angiography – Dye-based imaging to see blood vessel leakage, vasculitis, choroidal inflammation, and to differentiate active inflammatory lesions from scarring. NCBI

21. B-Scan Ultrasound – Used when media is opaque (e.g., dense vitreous inflammatory haze) to evaluate deeper structures, vitreous inflammation, or retinal detachment behind the cloudy view. NCBI

22. Fundus Photography – High-resolution photos of the back of the eye for documentation, monitoring progression or response to treatment. NCBI

23. MRI of the Orbit/Brain – When inflammation involves the optic nerve, neuro-ophthalmic structures, or if masquerading pathology is suspected (e.g., optic nerve inflammation vs. uveitis overlap), MRI provides soft tissue detail. NCBI

Non-Pharmacological Treatments

1. Discontinuation or substitution of the offending drug
   The first and most impactful step is to stop the medication causing the uveitis or switch to a safer alternative. Removing the trigger reduces continued immune activation and gives the inflammation a chance to settle. This alone often leads to substantial improvement. EyeWiki

2. Adequate rest and sleep hygiene
   Good sleep supports immune regulation. Poor or irregular sleep increases systemic inflammation through dysregulated cytokine production. Regular sleep (7–9 hours) helps the body calm down inflammatory pathways and supports healing. MDPI

3. Stress reduction techniques (meditation, breathing, mindfulness)
   Chronic stress elevates cortisol and inflammatory mediators, worsening immune-driven eye inflammation. Practices like mindfulness, deep breathing, and gentle yoga lower stress hormones and help modulate immune responses, reducing flare frequency. MDPI

4. Smoking cessation
   Tobacco smoke is pro-inflammatory and impairs microvascular circulation; smoking has been linked to worse outcomes in many autoimmune/inflammatory eye conditions. Quitting reduces oxidative stress and systemic immune activation. EatingWell

5. UV protection with sunglasses
   Ultraviolet light can irritate inflamed eyes and increase oxidative stress. Wearing broad-spectrum sunglasses outdoors shields the eye and reduces additional inflammatory stimulus. PMC

6. Artificial tears and ocular surface lubrication
   Inflammation often comes with surface dryness or irritation. Lubricating drops (preservative-free if chronic) soothe the ocular surface, reduce reflex tearing and discomfort, and create a better environment for recovery. This is supportive therapy and does not replace anti-inflammatory drugs. MDPI

7. Eyelid hygiene (warm compresses, lid cleaning)
   If concurrent blepharitis or meibomian gland dysfunction exists, cleaning lids and using warm compresses improves tear quality and reduces surface inflammation that can exacerbate uveitis symptoms indirectly. MDPI

8. Cold compresses for pain/photophobia relief
   Applying a clean, cool compress reduces localized pain and light sensitivity by vasoconstriction and numbing sensation temporarily. It is a safe symptomatic measure during acute flares. PMC

9. Control of systemic diseases (e.g., autoimmune conditions, infections)
   Underlying diseases such as rheumatoid arthritis or inflammatory bowel disease can amplify eye inflammation. Treating and stabilizing those diseases reduces the chance of recurring or worsening uveitis. Coordination with rheumatology/infectious disease specialists is important. SpringerLink

10. Anti-inflammatory diet (see “What to Eat” below)
    Eating foods rich in omega-3 fats, antioxidants, and low in processed pro-inflammatory ingredients lowers baseline systemic inflammation and supports ocular immune balance. EatingWellHealth

11. Weight management and regular moderate exercise
    Obesity is linked to chronic low-grade inflammation. Light to moderate physical activity improves circulation, reduces inflammatory cytokines, and helps immune regulation. Avoid overexertion during active eye flare. MDPI

12. Regular eye check-ups and early detection
    Frequent ophthalmology visits help catch new flares early, monitor complications (like glaucoma or cataract), and adjust interventions before irreversible damage. PMC

13. Hygiene to prevent secondary infection
    Keeping hands clean, avoiding rubbing eyes, and not sharing makeup/contact lenses lowers the risk of adding infectious inflammation to an already inflamed eye. MDPI

14. Avoiding eye trauma and irritation
    Mechanical irritation (rubbing, dust exposure) can worsen inflammation or break protective barriers. Protective eyewear in dusty/harsh environments reduces this risk. Retina Today

15. Blue-light and screen-time moderation
    While not a direct cause, reducing excessive screen exposure decreases eye strain and may prevent subjective worsening of symptoms during an active flare. MDPI

16. Proactive vaccination as appropriate
    Preventing systemic infections (e.g., herpes zoster in at-risk individuals) reduces infectious triggers that can complicate or mimic uveitis. Vaccination decisions should be coordinated with the eye doctor when immunosuppression is in use. SpringerLink

17. Avoiding known environmental or allergenic triggers
    If the uveitis is part of a broader inflammatory tendency, minimizing exposures (e.g., allergens, pollutants) helps keep baseline immune activation lower. MDPI

18. Education and self-monitoring
    Teaching patients the early signs of flare and how to self-assess vision, pain, or light sensitivity leads to faster presentation and treatment initiation. PMC

19. Collaborative care planning (multi-specialty communication)
    Ensuring the prescribing doctor (e.g., oncology, rheumatology) and the ophthalmologist communicate about potential offending drugs or emerging inflammation prevents delays in identifying drug-induced causes. Lippincott JournalsEyeWiki

20. Use of filters or adaptive lighting in living/work spaces
    Gentle ambient lighting and reduced glare can reduce discomfort from photophobia during active eye inflammation, aiding quality of life while healing. MDPI

---

Drug Treatments

Note: Always weigh benefits versus risks. Many require ophthalmologist supervision and sometimes systemic monitoring.

1. Topical Corticosteroids (e.g., Prednisolone acetate 1%)

   • Class: Corticosteroid, anti-inflammatory.

   • Dosage/Timing: Frequently initially (e.g., every 1–2 hours while awake), then tapered based on response.

   • Purpose: Reduce anterior segment inflammation rapidly.

   • Mechanism: Blocks inflammatory gene expression, reduces cytokines (e.g., TNF-α, interleukins), stabilizes cell membranes, and decreases vascular permeability.

   • Side Effects: Elevated intraocular pressure (glaucoma), cataract formation with long use, secondary infection risk. MDPI

2. Periocular or Intravitreal Corticosteroid Injections / Implants (e.g., Triamcinolone, Dexamethasone implant, Fluocinolone acetonide implant)

   • Class: Local corticosteroid delivery.

   • Dosage/Timing: Single injections or sustained-release implants (e.g., dexamethasone implant every ~3–6 months, fluocinolone implant lasts longer).

   • Purpose: Treat intermediate/posterior or refractory inflammation while minimizing systemic side effects.

   • Mechanism: Direct high local anti-inflammatory effect by suppression of immune cells and cytokines in the posterior segment.

   • Side Effects: Elevated eye pressure, cataract, risk of endophthalmitis, implant migration in rare cases. MDPIPMC

3. Systemic Corticosteroids (e.g., Prednisone 0.5–1 mg/kg/day initially)

   • Class: Systemic anti-inflammatory.

   • Dosage/Timing: Daily oral dosing, tapered over weeks as inflammation subsides.

   • Purpose: Control moderate-to-severe or posterior segment inflammation when topical/local therapy is insufficient.

   • Mechanism: Broad immunosuppression, inhibiting multiple inflammatory pathways and cytokine production.

   • Side Effects: Weight gain, hyperglycemia, hypertension, osteoporosis, mood changes, susceptibility to infection. SpringerLink

4. Methotrexate

   • Class: Antimetabolite / immunosuppressant.

   • Dosage/Timing: Weekly oral or subcutaneous (e.g., 7.5–25 mg/week), often with folinic acid to reduce toxicity.

   • Purpose: Steroid-sparing agent for chronic non-infectious uveitis to maintain long-term control.

   • Mechanism: Inhibits dihydrofolate reductase, reducing proliferation of immune cells and modulating inflammation.

   • Side Effects: Liver toxicity, bone marrow suppression, lung inflammation; requires blood monitoring. SpringerLink

5. Mycophenolate Mofetil

   • Class: Antimetabolite immunosuppressant.

   • Dosage/Timing: Typically 1,000–1,500 mg twice daily.

   • Purpose: Long-term control of immune-mediated ocular inflammation.

   • Mechanism: Inhibits inosine monophosphate dehydrogenase, blocking lymphocyte proliferation.

   • Side Effects: Diarrhea, increased infection risk, bone marrow suppression. SpringerLink

6. Azathioprine

   • Class: Purine analog / immunosuppressant.

   • Dosage/Timing: Often 1–3 mg/kg/day orally.

   • Purpose: Chronic uveitis as steroid-sparing therapy.

   • Mechanism: Interferes with DNA synthesis in proliferating immune cells, lowering immune response.

   • Side Effects: Liver toxicity, bone marrow suppression, increased infection risk. SpringerLink

7. Cyclosporine

   • Class: Calcineurin inhibitor / immunosuppressant.

   • Dosage/Timing: Variable; often 2.5–5 mg/kg/day in divided doses.

   • Purpose: Control refractory uveitis in patients who don’t respond to first-line agents.

   • Mechanism: Inhibits calcineurin pathway, reducing T-cell activation and cytokine release.

   • Side Effects: Kidney dysfunction, hypertension, tremor, gum hypertrophy. SpringerLink

8. Anti-TNF Biologics (e.g., Adalimumab, Infliximab)

   • Class: Biologic TNF-α inhibitors.

   • Dosage/Timing: Adalimumab often every other week subcutaneously; infliximab infusion schedule varies (e.g., every 4–8 weeks after loading).

   • Purpose: Treat moderate-to-severe non-infectious uveitis, especially when conventional immunosuppressants fail.

   • Mechanism: Block TNF-α, a key inflammatory cytokine driving immune-mediated eye inflammation.

   • Side Effects: Increased infection risk (including TB reactivation), infusion reactions, rare demyelinating disease. SpringerLinkLippincott Journals

9. Interleukin Inhibitors (e.g., Tocilizumab)

   • Class: IL-6 receptor antagonist.

   • Dosage/Timing: Usually intravenous or subcutaneous per protocol (e.g., every 4 weeks).

   • Purpose: Refractory uveitis not responsive to TNF inhibitors or conventional therapies.

   • Mechanism: Blocks IL-6 signaling, reducing inflammatory cascades in autoimmune inflammation.

   • Side Effects: Elevated liver enzymes, infection risk, gastrointestinal perforation (rare). SpringerLink

10. Local Nonsteroidal Immunomodulators (e.g., intravitreal methotrexate in select cases)

• Class: Local immunosuppressive / antimetabolite.

• Dosage/Timing: Injections per specialist protocol.

• Purpose: Control localized posterior segment inflammation when systemic therapy is contraindicated.

• Mechanism: Direct inhibition of immune cell proliferation in the vitreous or retinal tissues.

• Side Effects: Local irritation, potential toxicity to retina in high doses. SpringerLink

---

Dietary Molecular Supplements

1. Omega-3 Fatty Acids (EPA/DHA)

   • Dosage: Commonly 1–2 grams of combined EPA/DHA daily.

   • Function: Anti-inflammatory; helps reduce systemic inflammatory cytokines.

   • Mechanism: Compete with omega-6 precursors to shift eicosanoid balance toward less inflammatory mediators and increase resolvin production.

   • Evidence: Helps modulate immune activity and is supportive in ocular inflammatory conditions. MDPIEatingWell

2. Vitamin D

   • Dosage: Depending on deficiency, 1,000–4,000 IU daily (adjusted by blood level).

   • Function: Immune modulation; may lower autoimmune activity.

   • Mechanism: Vitamin D receptors regulate gene expression in immune cells, reducing pro-inflammatory Th1/Th17 responses.

   • Evidence: Low vitamin D is linked with increased risk/severity of inflammatory diseases; supplementation helps balance immune response. EatingWellMDPI

3. Curcumin (with black pepper/piperine for absorption)

   • Dosage: 500–1,000 mg of standardized extract twice daily with piperine.

   • Function: Antioxidant and anti-inflammatory.

   • Mechanism: Inhibits NF-κB pathway, decreasing cytokine production and oxidative damage in tissues.

   • Evidence: Animal and some human data suggest reduction in ocular inflammation; part of complementary therapies. PMCEBSCO

4. Resveratrol

   • Dosage: 100–500 mg daily (varies by formulation).

   • Function: Antioxidant, modulates inflammatory signaling.

   • Mechanism: Activates SIRT1 and inhibits inflammatory cytokine pathways, helping reduce oxidative stress and immune overactivation.

   • Evidence: Shown in preclinical and some clinical contexts to reduce inflammatory mediators. Healthbirdshot.org.uk

5. Zinc

   • Dosage: 15–30 mg elemental zinc daily.

   • Function: Supports immune system balance and antioxidant enzymes (e.g., superoxide dismutase).

   • Mechanism: Cofactor for many enzymes; stabilizes cell membranes and modulates cytokine production.

   • Evidence: Used in ocular health and seen in diets of uveitis patients in supportive roles. birdshot.org.ukEatingWell

6. Vitamin C

   • Dosage: 500–1,000 mg daily.

   • Function: Antioxidant, supports tissue repair.

   • Mechanism: Scavenges free radicals, regenerates other antioxidants, supports collagen stabilization in ocular structures.

   • Evidence: Lowers markers of oxidative stress that can amplify inflammation. Health

7. N-acetylcysteine (NAC)

   • Dosage: 600–1,200 mg twice daily.

   • Function: Antioxidant precursor to glutathione.

   • Mechanism: Increases intracellular glutathione, neutralizing oxidative stress that worsens inflammation.

   • Evidence: General inflammation reduction; beneficial in oxidative-stress–linked eye diseases. MDPI

8. Probiotics

   • Dosage: Follow product-specific dosing (common strains: Lactobacillus, Bifidobacterium).

   • Function: Modulate gut-immune axis to reduce systemic inflammation.

   • Mechanism: Promote healthy gut flora that produce anti-inflammatory short-chain fatty acids and reduce systemic immune activation.

   • Evidence: Indirect support in inflammatory diseases; gut health influences ocular immunity. MDPIEatingWell

9. Quercetin

   • Dosage: 500 mg twice daily.

   • Function: Flavonoid with anti-inflammatory and mast cell–stabilizing properties.

   • Mechanism: Inhibits histamine release and inflammatory enzymes (e.g., COX, LOX).

   • Evidence: Supports reduction in inflammatory signaling though ocular-specific data is limited; used in complementary regimens. Health

10. Green Tea Polyphenols (EGCG)

    • Dosage: 250–500 mg of standardized extract daily.

    • Function: Antioxidant and immune modulator.

    • Mechanism: Downregulation of inflammatory mediators and oxidative stress pathways in tissues.

    • Evidence: Preclinical data shows modulation of ocular inflammation; anecdotal use in supportive care. MDPI

Note: Always check for interactions especially when combining supplements with systemic immunosuppressants or corticosteroids. Discuss with the treating ophthalmologist before starting new supplements. Health

---

Regenerative / Stem Cell-Based (Hard Immunity) Therapies

1. Bone Marrow–Derived Mesenchymal Stem Cells (MSCs)

   • Dosage: Experimental dosing varies; preclinical models use millions of cells (e.g., 1–2 ×10^6 cells/kg) delivered intravenously or locally.

   • Function: Immune modulation and reduction of ocular inflammation.

   • Mechanism: MSCs secrete anti-inflammatory cytokines, induce regulatory T-cells, and suppress pathogenic immune cells, shifting environment from inflammatory to tolerogenic.

   • Evidence: Preclinical studies in uveitis models show reduced inflammation and retinal protection. PMCPMCResearchGate

2. Adipose-Derived MSCs

   • Dosage: Similar experimental ranges; delivered periocularly or systemically in trials.

   • Function & Mechanism: Comparable to bone marrow MSCs, with anti-inflammatory secretome and tissue-supporting effects.

   • Evidence: Early studies suggest modulation of autoimmune uveitis in animal models via immune regulation. PMCResearchGate

3. Umbilical Cord–Derived MSCs

   • Dosage: Clinical and preclinical dose-finding ongoing.

   • Function: Immune suppression and tissue repair.

   • Mechanism: Secretion of extracellular vesicles/exosomes carrying immunoregulatory molecules and growth factors to temper inflammation.

   • Evidence: Potential for ocular autoimmune diseases, with favorable safety profile in early-phase studies. PMCResearchGate

4. MSC-Derived Exosomes / Extracellular Vesicles

   • Dosage: Experimental; often quantified by protein content or particle number.

   • Function: Cell-free delivery of MSC immunomodulatory signaling.

   • Mechanism: Carry microRNAs and proteins that mimic parent MSC’s anti-inflammatory effects, reducing immune cell activation without risks of live cells.

   • Evidence: Shown to reduce uveitis severity in animal studies and are being explored as safer regenerative agents. PMCPMC

5. Preconditioned or Genetically Enhanced MSCs

   • Dosage: Tailored in research settings.

   • Function: Boosted anti-inflammatory output or targeted delivery.

   • Mechanism: Genetic modification or pre-treatment (e.g., with cytokines) enhances secretion of beneficial factors like IL-10, improving efficacy against ocular inflammation.

   • Evidence: Experimental stage; preclinical work suggests greater control of autoimmune uveitis. PMC

6. Combination MSC + Standard Immunomodulator Protocols

   • Dosage/Approach: MSC therapy paired with low-dose conventional immunosuppressants to achieve synergy.

   • Function: Reduce reliance on high-dose systemic drugs while maintaining disease control.

   • Mechanism: MSCs create a permissive immune regulatory milieu, allowing lower doses of other drugs to be effective.

   • Evidence: Early-phase translational studies are exploring these combinations to maximize safety and durability. PMC

Note: These approaches are largely experimental for uveitis; they are not yet standard of care and typically available only in clinical trials. Risks, long-term outcomes, and optimal dosing are still under investigation. PMCResearchGate

---

Surgical or Procedural Interventions

1. Cataract Surgery with Intraocular Lens (IOL) Implantation

   • Procedure: Removal of a cloudy lens (cataract) that develops from chronic inflammation or steroid use, followed by IOL placement.

   • Why Done: Restores vision lost due to uveitic cataract; requires inflammation to be quiet (usually ≥3 months) beforehand to reduce complications.

   • Evidence/Consideration: Careful perioperative inflammation control is key to success and lowering risk of vision-threatening complications. PMCAAO

2. Pars Plana Vitrectomy

   • Procedure: Removal of vitreous gel, inflammatory debris, membranes, or for diagnostic sampling.

   • Why Done: Clears persistent vitreous haze, treats complications like epiretinal membranes, and obtains material to rule out infection or malignancy when etiology is unclear.

   • Evidence: Helps both therapeutic and diagnostic challenges in chronic or unclear uveitis. PMCRetina Today

3. Glaucoma Surgery (e.g., Trabeculectomy or Tube Shunt)

   • Procedure: Creating new drainage pathways to lower intraocular pressure when medical therapy fails.

   • Why Done: Uveitis can lead to secondary glaucoma from trabecular meshwork inflammation or steroid-induced pressure rise; uncontrolled pressure damages optic nerve.

   • Evidence: Surgical intervention is needed when conservative measures do not protect vision. Retina Today

4. Synechiolysis (Breaking of Posterior or Peripheral Synechiae)

   • Procedure: Mechanical or pharmacologic (e.g., with mydriatics) breaking of adhesions between iris and lens or cornea.

   • Why Done: Restores pupil mobility, prevents angle closure, and improves aqueous flow that can be blocked by these scar adhesions formed during inflammation.

   • Evidence: Part of anterior segment management in chronic anterior uveitis. PMC

5. Implantation of Sustained-Release Steroid Device (e.g., Fluocinolone Acetonide Implant)

   • Procedure: Surgical placement of a tiny implant inside the eye that slowly releases corticosteroid over months to years.

   • Why Done: Provides long-term control of posterior or intermediate uveitis without frequent injections or high systemic exposure.

   • Evidence: Effective for chronic non-infectious uveitis when other therapy is insufficient or systemic side effects are prohibitive. MDPI

---

Preventions

1. Review Medication List Before Starting New Drugs
   Talk to your doctor about uveitis risk from proposed medications, especially bisphosphonates, rifabutin, immune checkpoint inhibitors, or cancer therapies. Lippincott JournalsEyeWiki

2. Avoid Known Offending Drugs When Alternatives Exist
   If you have a history of drug-induced uveitis with a certain class (e.g., nitrogen-containing bisphosphonates), ask about switching to non-nitrogenated options or alternative therapies. PMC

3. Control Underlying Systemic Inflammatory or Autoimmune Diseases
   Stable systemic disease reduces the “background” immune activation that can make the eye more prone to inflammation. SpringerLink

4. Early Detection Through Regular Eye Exams
   Periodic ophthalmic follow-up lets you catch mild inflammation before it escalates into vision-threatening disease. PMC

5. Vaccinate Appropriately (e.g., against herpes zoster if indicated)
   Prevent infections that could either mimic or trigger ocular inflammation; coordinate timing when on immunosuppression. SpringerLink

6. Avoid Eye Trauma and Irritation
   Protect eyes in risky environments to prevent secondary inflammation or exacerbation of existing inflammation. Retina Today

7. Quit Smoking
   Smoking fuels systemic inflammation and worsens outcomes for immune-mediated eye disease. EatingWell

8. Use Sunglasses to Reduce UV and Phototoxic Stress
   Shielding from environmental stressors decreases additive inflammatory stimuli. PMC

9. Balance Diet Toward Anti-inflammatory Foods
   Eating rich omega-3s, antioxidants, and minimizing processed pro-inflammatory items lowers chronic inflammation baseline. Health

10. Coordinate Multi-specialty Care for High-Risk Therapies
    If starting drugs known to cause uveitis (e.g., cancer immunotherapies), make sure ophthalmology is in the loop for baseline and follow-up assessment. Lippincott JournalsEyeWiki

---

When to See a Doctor

You should seek prompt ophthalmological evaluation if you experience any of the following:

• Sudden eye redness or severe pain.

• Light sensitivity (photophobia) that is new or worsening.

• Blurred vision, floaters, or dark shadows in vision.

• Decrease in visual clarity or field.

• Persistent headache with visual changes.

• Symptoms beginning after starting a new medication.

• No improvement—or worsening—despite initial home care (e.g., artificial tears).

• Signs of elevated eye pressure like halos around lights or eye ache.

• Recurrence after previous uveitis even if mild.

• Any signs suggestive of infection (pus-like discharge, fever accompanying eye symptoms). PMCEyeWiki

---

What to Eat and What to Avoid

What to Eat (Anti-Inflammatory, Supportive Foods)

1. Fatty fish (salmon, mackerel) – Rich in omega-3s to reduce inflammatory mediators. EatingWell

2. Leafy green vegetables (spinach, kale) – High in antioxidants and polyphenols that inhibit oxidative stress. EatingWell

3. Berries (blueberries, strawberries) – Polyphenol-rich, help suppress free radicals. EatingWell

4. Nuts (walnuts, almonds) – Provide healthy fats and micronutrients. EatingWell

5. Olive oil (extra virgin) – Source of anti-inflammatory monounsaturated fats and phenolics. EatingWell

6. Turmeric with black pepper – Curcumin absorption enhanced by piperine; anti-inflammatory. PMC

7. Ginger – Contains gingerol, reduces inflammatory markers. EatingWell

8. Probiotic-rich foods (yogurt, kefir) – Support gut-immune balance. MDPI

9. Whole grains – Provide fiber and feed beneficial gut bacteria that produce anti-inflammatory short-chain fatty acids. EatingWell

10. Hydration (water) – Supports metabolic clearance of inflammatory byproducts; avoid dehydration-induced stress. MDPI

What to Avoid

1. Processed foods high in trans fats and refined carbs – Promote systemic inflammation. Health

2. Excess added sugar – Increases pro-inflammatory cytokines. Health

3. High omega-6 vegetable oils (e.g., excessive corn/soy oils) – Skew balance toward inflammatory eicosanoids if not balanced with omega-3s. EatingWell

4. Excessive alcohol – Can impair immune regulation and liver function affecting systemic inflammation. MDPI

5. Smoking / tobacco products – Fuels oxidative and immune stress. EatingWell

6. Excessive caffeine (if it causes sleep disruption) – Sleep loss indirectly increases inflammation. MDPI

7. Artificial additives/ preservatives in heavily processed snacks – May stress immune system in sensitive individuals. Health

8. High-sodium ultra-processed meals – May worsen vascular inflammation and ocular perfusion in sensitive patients. (Inference based on vascular inflammation literature). MDPI

9. Uncontrolled high glycemic index diets – Promote glycation and oxidative stress. Health

10. Excessive red meat / saturated fat (if paired with low fiber) – May contribute to a pro-inflammatory milieu. EatingWell

---

Frequently Asked Questions (FAQs)

1. What is drug-induced uveitis?
   It is inflammation inside the eye caused by a medication. The eye reacts to the drug by mounting an immune or inflammatory response that affects the uvea. PMC

2. Which drugs most commonly cause uveitis?
   Common culprits include bisphosphonates (especially pamidronate), rifabutin, immune checkpoint inhibitors, BRAF/MEK inhibitors, and certain antibiotics or systemic agents. PMCLippincott JournalsPMC

3. How soon after taking a drug does uveitis begin?
   It varies by drug but often within days to weeks of starting the medication. Some agents (like bisphosphonates) may cause uveitis 1–6 days after exposure. PMCPMC

4. Can drug-induced uveitis cause permanent vision loss?
   If not treated timely or if complications develop (like glaucoma, cataract, or macular edema), permanent vision loss is possible. Early diagnosis and control of inflammation dramatically reduce this risk. PMCPMC

5. How is drug-induced uveitis diagnosed?
   Through a detailed eye exam including slit-lamp examination, intraocular pressure measurement, dilated fundoscopy, and sometimes imaging or lab work to rule out other causes. Medication history is critical. EyeWiki

6. Do I have to stop the offending drug?
   In most cases, yes—stopping or switching the drug is a key step. Your doctor will weigh the benefits versus risks, especially if it’s a critical medication; sometimes alternatives or supportive therapy are chosen. EyeWiki

7. Are steroids safe for treating uveitis?
   Yes, when used appropriately. Topical, local (injection/implant), or systemic steroids are mainstays, but they require monitoring due to possible side effects like elevated eye pressure or systemic effects. MDPISpringerLink

8. Can diet or supplements help?
   Yes. Anti-inflammatory foods and supplements (like omega-3s, vitamin D, curcumin, resveratrol) support immune balance and may reduce flare frequency or intensity. They are adjuncts, not replacements for medical therapy. EatingWellHealth

9. When is surgery needed?
   Surgery may be needed for complications (cataract, glaucoma, persistent vitreous haze) or to deliver long-acting therapy (e.g., steroid implant). Adequate control of inflammation before surgery is essential. PMCMDPI

10. Is drug-induced uveitis contagious?
    No. It is an inflammatory reaction, not an infection you can pass to others. EyeWiki

11. Can uveitis come back after treatment?
    Yes, especially if the trigger returns or underlying immune dysregulation persists. Maintenance therapy and monitoring reduce recurrence. SpringerLink

12. Are stem cell therapies available for uveitis?
    They are currently experimental. Mesenchymal stem cells and their exosomes show promise in early studies for modulating inflammation, but they are not yet standard treatment and usually only offered in clinical trials. PMCResearchGate

13. Can I prevent drug-induced uveitis?
    Yes, by reviewing new medications with your doctor, avoiding known offenders if possible, controlling systemic disease, and having regular eye check-ups. Lippincott JournalsEyeWiki

14. What happens if I delay seeing a doctor?
    Delay can lead to worsening inflammation, more complications (glaucoma, cataract, scarring), and higher chance of long-term visual damage. Early treatment is safer and usually simpler. PMC

15. Can underlying autoimmune disease change treatment?
    Yes. If uveitis is part of a larger autoimmune condition, therapy often includes systemic immunomodulators beyond local eye drops, and coordination with other specialists is vital. SpringerLink

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 02, 2025.